| scholarly article | Q13442814 |
| P356 | DOI | 10.1099/0022-1317-78-9-2209 |
| P698 | PubMed publication ID | 9292008 |
| P2093 | author name string | Wang Z | |
| Schiller JT | |||
| Dillner J | |||
| Christensen N | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | monoclonal antibody | Q422248 |
| P304 | page(s) | 2209-2215 | |
| P577 | publication date | 1997-09-01 | |
| P1433 | published in | Journal of General Virology | Q6295245 |
| P1476 | title | A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera | |
| P478 | volume | 78 ( Pt 9) |
| Q33514126 | A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females |
| Q40238745 | A deletion and point mutation study of the human papillomavirus type 16 major capsid gene |
| Q36448778 | A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5 |
| Q45362152 | A molecular dynamics study of loop fluctuation in human papillomavirus type 16 virus-like particles: a possible indicator of immunogenicity |
| Q37162220 | Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines |
| Q36088309 | Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles |
| Q24796150 | Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope |
| Q33813986 | Characterization of a major neutralizing epitope on human papillomavirus type 16 L1 |
| Q34033805 | Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy |
| Q36240497 | Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV) |
| Q35155333 | Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16 |
| Q34089066 | Comparison of papillomavirus and immunodeficiency virus evolutionary patterns in the context of a papillomavirus vaccine |
| Q37671423 | Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities |
| Q34477334 | Development of a highly thermostable, adjuvanted human papillomavirus vaccine |
| Q34256293 | Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity |
| Q57063346 | Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid |
| Q47132009 | Escherichia coli-derived virus-like particles in vaccine development |
| Q36558193 | Evidence for Placental HPV Infection in Both HIV Positive and Negative Women |
| Q42785059 | Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1. |
| Q47136931 | High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16. |
| Q35596329 | Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study) |
| Q33908917 | Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers |
| Q33469751 | Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications |
| Q39683911 | Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses |
| Q36283939 | Immune responses to human papillomavirus |
| Q34305225 | Immunity to oncogenic human papillomaviruses |
| Q73414358 | Immunological analyses of human papillomavirus capsids |
| Q43616965 | Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope |
| Q45722771 | Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11. |
| Q36540127 | Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies |
| Q33825698 | Multiplexed serologic assay for nine anogenital human papillomavirus types |
| Q35947703 | Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition |
| Q33910699 | Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18 |
| Q35155632 | Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses |
| Q34315981 | Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells |
| Q40610561 | Quantitative and epitope-specific antigenicity analysis of the human papillomavirus 6 capsid protein in aqueous solution or when adsorbed on particulate adjuvants |
| Q96171815 | Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles |
| Q40572162 | Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. |
| Q45744233 | Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia |
| Q100519112 | Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs |
| Q41605239 | Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization |
| Q36281141 | The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy |
| Q37198519 | The papillomavirus major capsid protein L1. |
| Q35677525 | The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population |
| Q36793117 | Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination |
| Q34089060 | Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection |
Search more.